

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

**(I) GRANT OF OPTIONS UNDER THE 2021 SHARE OPTION SCHEME;
(II) GRANT OF AWARDS TO EMPLOYEES UNDER
THE 2021 SHARE AWARD SCHEME; AND
(III) NON-EXEMPT CONNECTED TRANSACTION – PROPOSED
CONNECTED GRANT TO DIRECTORS**

(I) GRANT OF OPTIONS UNDER THE 2021 SHARE OPTION SCHEME

References are made to the announcement and circular of the Company in respect of, among others, the adoption of the 2021 Share Option Scheme dated July 2, 2021 and August 11, 2021, respectively.

Pursuant to Rule 17.06A of the Listing Rules, the Board announces that at the meeting of the Board held on September 9, 2022, it resolved to grant 13,060,000 Options in aggregate to 300 Grantees, among which (i) 2,160,000 Options were granted to Mr. Liu, an executive Director and the CEO, who is responsible for overall strategic planning, business direction and daily management of the Company; (ii) 137,000 Options were granted to Dr. Hu, an executive Director and the chief development officer of the Company, who is primarily responsible for participating in strategic planning and management of chemistry, manufacturing and controls and regulatory affairs of the Company; and (iii) 10,763,000 Options in aggregate to other 298 Grantees, in accordance with the terms of the 2021 Share Option Scheme, subject to the acceptance of the Grantees.

Details of the Grant of Options

The details of the Options granted to the Grantees are as follows:

Grant Date	September 9, 2022
Number of Options granted	13,060,000 Options, among which (i) 2,160,000 Options were granted to Mr. Liu, (ii) 137,000 Options were granted to Dr. Hu; and (iii) 10,763,000 Options were granted to other 298 Grantees, who are all employees of the Group

Total number of new Shares to be subscribed for upon exercise of the Options granted:	13,060,000
Exercise price of the Options granted	<p>HK\$11.41 per Share, which represents the highest of:</p> <ul style="list-style-type: none"> (i) the closing price of the Shares of HK\$10.52 as stated in the daily quotations sheet issued by the Stock Exchange on the Grant Date; (ii) the average closing price of the Shares of HK\$11.41 as stated in the daily quotations sheets issued by the Stock Exchange for five (5) business days immediately preceding the Grant Date; and (iii) the nominal value of the Share, which is US\$0.00001 each.
Exercise period of the Options	Subject to the vesting period as set out below, the exercise period of the Options shall be ten (10) years from the Grant Date and the Options shall lapse at the expiry of the exercise period.
Vesting period	<p>2,160,000 Options granted to Mr. Liu shall vest as follows:</p> <ul style="list-style-type: none"> (a) 25% of the Options shall vest immediately on the Grant Date; (b) 25% of the Options shall vest on the first anniversary of the Grant Date, conditional upon the achievement of certain performance targets relating to the overall performance of the Company as set out in the grant letter entered into between Mr. Liu and the Company, including R&D and registration progress of drug candidates, marketing and sales of commercialized products, daily operation and management of the Group. Partial achievement of the performance targets will result in proportionate vesting at the Board's discretion; (c) 25% of the Options shall vest on the second anniversary of the Grant Date, conditional upon the performance targets to be achieved by the Company and/or Mr. Liu, which shall be determined by the Board in due course; and (d) 25% of the Options shall vest on the third anniversary of the Grant Date, conditional upon the performance targets to be achieved by the Company and/or Mr. Liu, which shall be determined by the Board in due course.

137,000 Options granted to Dr. Hu and 10,763,000 Options granted to other 298 Grantees shall vest as follows:

- (a) 10% of the Options shall vest on the first anniversary of the Grant Date;
- (b) 20% of the Options shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the first anniversary of the Grant Date to the second anniversary of the Grant Date;
- (c) 30% of the Options shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the second anniversary of the Grant Date to the third anniversary of the Grant Date;
- (d) 40% of the Options shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the third anniversary of the Grant Date to the fourth anniversary of the Grant Date.

The vesting of the Options granted to Dr. Hu and other Grantees is conditional upon the achievement of the performance targets by Dr. Hu or relevant Grantee set out in his/her grant letter entered into between Dr. Hu or such Grantee and the Company, partial achievement of which will result in proportionate vesting.

The Remuneration Committee has reviewed and fully considered the vesting schedule of the Options granted to Mr. Liu and is of view that, (i) Mr. Liu, as an executive Director and the CEO, has made significant contributions to the Company in achieving the Group's R&D and commercialization milestones; (ii) the vesting arrangement for the first batch of Options granted to Mr. Liu serves as the Board's appreciation and recognition of Mr. Liu's contribution towards the growth of the Group; and (iii) the vesting arrangement for the remaining Options granted to Mr. Liu will provide sufficient incentive to retain Mr. Liu and motivate him to create more value in the Group's long-term development. Therefore, the Remuneration Committee is of view that the vesting arrangement for the Options granted to Mr. Liu will closely align the interests and benefits of the Company, the Board and the management of the Group, and thus is appropriate and reasonable and in the interests of the Company and its Shareholders as a whole.

Grant to Directors

Among the total 13,060,000 Options granted, 2,160,000 Options were granted to Mr. Liu and 137,000 Options were granted to Dr. Hu, each of whom is an executive Director. The details of such grants are as follows:

Grantee	Position held in the Company	Number of Options granted
Mr. Liu	Executive Director and CEO	2,160,000
Dr. Hu	Executive Director and chief development officer	137,000
	Total	2,297,000

Pursuant to Rule 17.04(1) of the Listing Rules, the grant of Options to Mr. Liu and Dr. Hu had been approved by the independent non-executive Directors.

None of the Grant of Options will be subject to approval by the Independent Shareholders, and save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them.

Reason for and Benefits of the Grant of Options

The purposes of the Grant of Options are to (i) retain, incentivize and reward the Directors and other employees of the Group, and (ii) encourage the Directors and other employees to work towards enhancing the value of the Company and its Shares.

(II) GRANT OF AWARDS TO EMPLOYEES UNDER THE 2021 SHARE AWARD SCHEME

References are made to the announcements and/or circular of the Company in respect of, among others, the adoption of the 2021 Share Award Scheme, the 2021 Award Scheme Specific Mandate, and the amendments to the Scheme Rules dated July 2, 2021, August 11, 2021 and December 3, 2021, respectively.

The Board announces that on September 9, 2022, it resolved to grant Awards representing a total of 10,763,000 underlying Award Shares to 298 Selected Participants under the 2021 Share Award Scheme, among which (i) 10,203,000 Award Shares will be satisfied by the Shares to be allotted and issued under the 2022 Award Scheme Specific Mandate; and (ii) 560,000 Award Shares will be satisfied by the Shares allotted and issued to the Trustee under the 2021 Award Scheme Specific Mandate. The grant will take effect upon the satisfaction of certain conditions, including the approval of the 2022 Award Scheme Specific Mandate by the Shareholders at the EGM and the Company receiving the approval from the Stock Exchange for the listing of and the permission to deal in the 10,763,000 Award Shares. All of the Selected Participants are employees of the Group and none of them is a connected person of the Company or an associate of any connected person of the Company.

The 10,763,000 Award Shares granted to the Selected Participants represent approximately 1.6% of the issued share capital of the Company as of the date of this announcement with an aggregate value of approximately HK\$113.2 million, calculated based on the closing price of HK\$10.52 per Share as stated in the daily quotations sheet issued by the Stock Exchange on the Grant Date.

For the purpose of clarification, pursuant to the Scheme Rules, the total number of Shares underlying all grants made pursuant to the 2021 Share Award Scheme (excluding Award Shares that have been forfeited in accordance with the 2021 Share Award Scheme) shall not exceed 5% of the total number of Shares in issue from time to time during the period of the 2021 Share Award Scheme, being 33,596,771 Shares as of the Grant Date. The aggregate number of Shares underlying the Awards granted under the 2021 Award Scheme Specific Mandate (excluding Award Shares that have been forfeited in accordance with the 2021 Share Award Scheme) and the 2022 Award Scheme Specific Mandate does not exceed such scheme limit.

Details of the Grant of Awards

The details of the Award Shares granted to the Selected Participants are as follows:

Grant Date	September 9, 2022
Number of Award Shares underlying Awards granted	10,763,000
Purchase price of the Awards granted	Nil
Market price of the Shares on the Grant Date	the closing price of the Shares of HK\$10.52 per Share as stated in the daily quotations sheet issued by the Stock Exchange on the Grant Date
Vesting period	Awards granted to 298 employees of the Group shall vest as follows: <ul style="list-style-type: none">(a) 10% of the Awards shall vest on the first anniversary of the Grant Date;(b) 20% of the Awards shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the first anniversary of the Grant Date to the second anniversary of the Grant Date;(c) 30% of the Awards shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the second anniversary of the Grant Date to the third anniversary of the Grant Date;(d) 40% of the Awards shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the third anniversary of the Grant Date to the fourth anniversary of the Grant Date.

The vesting of the Awards granted to the Selected Participants is conditional upon the achievement of the performance targets by the Selected Participant set out in his/her grant letter entered into between such Selected Participant and the Company, partial achievement of which will result in proportionate vesting.

The 2021 Share Award Scheme does not constitute a share option scheme under Chapter 17 of the Listing Rules and is a discretionary scheme of the Company. Further details of the 2021 Share Award Scheme are set out in the announcements of the Company dated July 2, 2021 and December 3, 2021, and the circular of the Company dated August 11, 2021.

The issue and allotment of the Award Shares under the 2022 Award Scheme Specific Mandate to Selected Participate shall be subject to (i) the approval of the 2022 Award Scheme Specific Mandate by the Independent Shareholders at the EGM; and (ii) the Listing Committee of the Stock Exchange having granted the approval for the listing of, and permission to deal in, 10,763,000 Shares which may be issued pursuant to the Awards granted under the 2021 Share Award Scheme. An application will be made to the Stock Exchange for the listing of and permission to deal in such Shares.

(III) NON-EXEMPT CONNECTED TRANSACTION – PROPOSED CONNECTED GRANT TO DIRECTORS

The Board is pleased to announce that at the meeting of the Board held on September 9, 2022, it resolved to grant Awards representing a total of 4,457,000 underlying Award Shares to Mr. Liu and Dr. Hu, namely the Connected Grantees, in accordance with the Scheme Rules, subject to acceptance by Mr. Liu and Dr. Hu and the approval of the Independent Shareholders' at the EGM. The Proposed Connected Grant shall be satisfied by the issue and allotment of new Shares to the Trustee pursuant to the 2022 Award Scheme Specific Mandate and in accordance with the Scheme Rules.

Subject to the Independent Shareholders' approval of the Proposed Connected Grant at the EGM, the maximum number of Award Shares that may be issued to Mr. Liu and Dr. Hu would be 4,320,000 Shares and 137,000 Shares, respectively, representing approximately 0.64% and 0.02% of the Company's issued share capital as of the date of this announcement and approximately 0.63% and 0.02% of the Company's enlarged issued share capital after the said issue and allotment, respectively (assuming there is no change in the issued share capital of the Company from the date of this announcement and up to the date of allotment of the new Shares, other than the issue and allotment of new Shares in accordance with the 2022 Award Scheme Specific Mandate).

Details of the Proposed Connected Grant to Directors

The details of the Award Shares granted to the Directors are as follows:

Grant Date	September 9, 2022
Number of Award Shares underlying Awards granted	4,457,000 Award Shares, out of which (i) 4,320,000 Award Shares will be granted to Mr. Liu, and (ii) 137,000 Award Shares will be granted to Dr. Hu
Purchase price of the Awards granted	Nil
Market price of the Shares on the Grant Date	the closing price of the Shares of HK\$10.52 per Share as stated in the daily quotations sheet issued by the Stock Exchange on the Grant Date

Vesting period

4,320,000 Awards to be granted to Mr. Liu shall vest as follows:

- (a) 25% of the Awards shall vest immediately on the Grant Date;
- (b) 25% of the Awards shall vest on the first anniversary of the Grant Date, conditional upon the achievement of certain performance targets relating to the overall performance of the Company as set out in the grant letter entered into between Mr. Liu and the Company, including R&D and registration progress of drug candidates, marketing and sales of commercialized products, daily operation and management of the Group. Partial achievement of the performance targets will result in proportionate vesting at the Board's discretion;
- (c) 25% of the Awards shall vest on the second anniversary of the Grant Date, conditional upon the performance targets to be achieved by the Company and/or Mr. Liu, which shall be determined by the Board in due course; and
- (d) 25% of the Awards shall vest on the third anniversary of the Grant Date, conditional upon the performance targets to be achieved by the Company and/or Mr. Liu, which shall be determined by the Board in due course.

137,000 Awards to be granted to Dr. Hu shall vest as follows:

- (a) 10% of the Awards shall vest on the first anniversary of the Grant Date;
- (b) 20% of the Awards shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the first anniversary of the Grant Date to the second anniversary of the Grant Date;
- (c) 30% of the Awards shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the second anniversary of the Grant Date to the third anniversary of the Grant Date;
- (d) 40% of the Awards shall vest in four equal instalments (with each instalment vesting at the end of each quarter) during the period from the third anniversary of the Grant Date to the fourth anniversary of the Grant Date.

The vesting of the Awards to be granted to Dr. Hu is conditional upon the achievement of the performance targets by Dr. Hu set out in his grant letter entered into between him and the Company, partial achievement of which will result in proportionate vesting.

The Remuneration Committee has reviewed and fully considered the vesting schedule of the Awards granted to Mr. Liu and is of view that, (i) Mr. Liu, as an executive Director and the CEO, has made significant contributions to the Company in achieving the Group's R&D and commercialization milestones; (ii) the vesting arrangement for the first batch of Awards granted to Mr. Liu serves as the Board's appreciation and recognition of Mr. Liu's contribution towards the growth of the Group; and (iii) the vesting arrangement for the remaining Awards granted to Mr. Liu will provide sufficient incentive to retain Mr. Liu and motivate him to create more value in the Group's long-term development. Therefore, the Remuneration Committee is of view that the vesting arrangement for the Awards granted to Mr. Liu will closely align the interests and benefits of the Company, the Board and the management of the Group, and thus is appropriate and reasonable and in the interests of the Company and its Shareholders as a whole.

Other than the relevant restrictions set out in the Listing Rules, there are no restrictions on the subsequent sale of the Award Shares. As of the date of this announcement, each of Mr. Liu and Dr. Hu is interested in 69,633,490 and 4,038,758 Shares and/or underlying Shares, respectively, representing approximately 10.36% and 0.60% of the total issued share capital of the Company, respectively, as notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO.

Market Value

The closing price of the Shares on the Grant Date as quoted on the Stock Exchange is HK\$10.52 per Share. The average closing price of the Shares for the five consecutive trading days immediately preceding the Grant Date as quoted on the Stock Exchange is HK\$11.41 per Share. Based on the closing price of HK\$10.52 per Share on the Grant Date, the market value of the Awards granted to the Connected Grantees amounts to approximately HK\$46.9 million.

Conditions Precedent

The issue and allotment of a total of 4,457,000 Connected Shares to Mr. Liu and Dr. Hu shall be subject to (i) the approval of the 2022 Award Scheme Specific Mandate and the Connected Grant Specific Mandate by the Independent Shareholders at the EGM; and (ii) the Listing Committee of the Stock Exchange having granted the approval for the listing of, and permission to deal in the Connected Shares to be issued under the 2021 Share Award Scheme. An application will be made to the Stock Exchange for the listing of and permission to deal in the Connected Shares.

Information about the Group

The Group is an ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. The vision of the Group is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. To date, the Group has a portfolio of 24 drug assets, covering all major front- and back-of-the-eye diseases, among which seven key drug candidates are in phase III clinical trial stage.

Reasons for the Proposed Connected Grant

The 2021 Share Award Scheme and the Proposed Connected Grant thereunder is part of the Company's remuneration policy, the purpose of which is to closely align the interests and benefits of the Company, the Board and the management of the Group in order to maximize the motivation of the executive Directors and senior management. The Proposed Connected Grant aims to provide sufficient incentive to retain and motivate Mr. Liu and Dr. Hu to participate in the formulation of strategy and long-term development of the Company and to recognize their contribution to the growth of the Company. Retaining Mr. Liu and Dr. Hu is highly beneficial for the Group's development and expansion, and can avoid potential disruption to the operation of the Group resulting from the lack of continuity of leadership. In this regard, the Directors (excluding Mr. Liu and Dr. Hu, and also independent non-executive Directors whose view will be given after considering the advice of Gram Capital) consider that the terms of the Proposed Connected Grant are fair and reasonable and in the best interests of the Company and the Shareholders as a whole.

Listing Rules Implications

Each of Mr. Liu and Dr. Hu is an executive Director and a connected person of the Company pursuant to Rule 14A.07 of the Listing Rules. Therefore, the Proposed Connected Grant and the proposed issue and allotment of the Connected Shares to Mr. Liu and Dr. Hu under the Proposed Connected Grant shall constitute a connected transaction of the Company under Chapter 14A of the Listing Rules and shall be subject to the announcement, circular and Independent Shareholders' approval requirements under the Listing Rules.

The EGM will be convened and held to consider, and if thought fit, approve, among other things, the Proposed Connected Grant and the issue and allotment of the Connected Shares to Mr. Liu and Dr. Hu.

To the best of the Directors' knowledge, information and belief, save for Mr. Liu and Dr. Hu and their respective associates, no other Shareholder is required to abstain from voting on the resolutions to approve, among other things, the Proposed Connected Grant and the issue and allotment of the Connected Shares to Mr. Liu and Dr. Hu.

The Independent Board Committee comprising Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG, being the independent non-executive Directors who are not Connected Grantees, has been formed to advise the Independent Shareholders on the issue and allotment of the Connected Shares to the Connected Grantees. The Independent Board Committee has appointed Gram Capital as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in this regard.

The Company will despatch a circular containing, among other things, (i) further details on the Proposed Connected Grant and the issue and allotment of the Connected Shares and the 2022 Award Scheme Specific Mandate, (ii) a letter of advice from the Independent Board Committee to the Independent Shareholders, (iii) a letter of advice from Gram Capital to the Independent Board Committee and the Independent Shareholders in respect of the Proposed Connected Grant and the issue and allotment of the Connected Shares to the Connected Grantees, and (iv) other relevant resolutions to be considered at the EGM, together with the notice convening the EGM to the Shareholders as soon as practicable in accordance with the Listing Rules. Given additional time is required for the Company to prepare and finalize certain information to be included in the circular, the despatch of circular is expected to be on or before October 14, 2022.

Each of Mr. Liu and Dr. Hu has abstained from voting on the relevant resolutions of the Board on the Proposed Connected Grant. Save as disclosed above, none of the other Directors had any interest in the Proposed Connected Grant and therefore no other Director abstained from voting on the relevant resolutions of the Board in respect of the Proposed Connected Grant.

Details of the Proposed Connected Grant (if approved by the Independent Shareholders at the EGM) will be disclosed in the Company's annual reports and accounts in accordance with Rule 14A.69 of the Listing Rules as well as the Company's annual reports and interim reports in accordance with the requirements under Chapter 17 of the Listing Rules as amended from time to time.

DEFINITIONS

“2021 Award Scheme Specific Mandate”	the specific mandate sought from the Shareholders at the extraordinary general meeting held on August 31, 2021 to grant the authority to the Board for the issue and allotment of the 18,936,000 Award Shares underlying the Awards granted or to be granted by the Company under the 2021 Share Award Scheme from time to time
“2021 Share Award Scheme”	the share award scheme adopted by the Company on July 2, 2021 and amended from time to time
“2021 Share Option Scheme”	the share option scheme adopted by the Board in accordance with the rules thereof on July 2, 2021 and approved by the Shareholders on August 31, 2021
“2022 Award Scheme Specific Mandate”	the specific mandate to be sought from the Shareholders at the EGM to grant the authority to the Board for the issue and allotment of the 14,660,000 Award Shares (being approximately 2.18% of the total Shares in issue as of the Grant Date rounded down to nearest whole board lot of 500 Shares, comprising 10,203,000 Shares underlying the Awards granted to employees under the Grant of Awards and 4,457,000 Connected Shares proposed to be granted to Mr. Liu and Dr. Hu which is to be approved by the Independent Shareholders) underlying the Awards granted or to be granted by the Company under the Grant of Awards and Proposed Connected Grant
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Award(s)”	award(s) granted by the Board to a Selected Participant or a Director under the 2021 Share Award Scheme
“Award Share(s)”	the Share(s) granted to a Selected Participant or a Director in Award(s)
“Board”	the board of directors of the Company
“CEO”	the chief executive officer of the Company

“China” or “the PRC”	the People’s Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires, references in this announcement to “China” and the “PRC” do not include Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Company”	Ocumension Therapeutics (歐康維視生物), an exempted company with limited liability incorporated in the Cayman Islands on February 27, 2018 with its Shares listed on the Main Board of the Stock Exchange
“Connected Grant Specific Mandate”	the specific mandate to be sought from the Shareholders at the EGM to grant the authority to the Board for the issue and allotment of the Connected Shares underlying the Awards to be granted by the Company under the Proposed Connected Grant
“Connected Grantee(s)”	the eligible person(s) who has/have been granted Award(s) in accordance with the Scheme Rules and is/are connected person(s) of the Company
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Connected Share(s)”	the 4,457,000 Award Shares proposed to be issued and allotted underlying the Awards granted by the Company to Mr. Liu and Dr. Hu under the Proposed Connect Grant
“Director(s)”	director(s) of the Company
“Dr. Hu”	Dr. Zhaopeng HU, an executive Director and the chief development officer of the Company
“EGM”	the extraordinary general meeting of the Company to be held for the purpose of, among other things, considering and, if thought fit, approving, among other things, the Proposed Connected Grant, the issue and allotment of the Connected Shares, the 2022 Award Scheme Specific Mandate and the transactions contemplated thereunder
“Grant Date”	the date on which the grant of an Award or an Option (as the case may be) is made to a Selected Participant or a Director
“Grant of Options”	the grant of 2,160,000 Options to Mr. Liu, 137,000 Options to Dr. Hu and 10,763,000 Options to other 298 Grantees, respectively, under the 2021 Share Option Scheme
“Grant of Awards”	the grant of 10,763,000 Award Shares to 298 Selected Participants under the 2021 Share Award Scheme
“Grantee(s)”	any eligible person who accepts an offer in accordance with the terms of the 2021 Share Option Scheme

“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Independent Board Committee”	an independent board committee of the Board comprising Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG, the independent non-executive Directors who are not Connected Grantees, established for the purpose of advising the Independent Shareholders on the Proposed Connected Grant, the issue and allotment of the Connected Shares and transactions contemplated thereunder
“Independent Financial Adviser” or “Gram Capital”	Gram Capital Limited, a licensed corporation to carry out Type 6 (advising on corporate finance) regulated activity under the SFO and has been appointed as the independent financial adviser to the Independent Board Committee and the Independent Shareholders in relation to the issue and allotment of the Connected Shares to the Connected Grantees and transactions contemplated thereunder
“Independent Shareholders”	independent Shareholders other than the Connected Grantees and their respective associates
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Mr. Liu”	Mr. Ye LIU, an executive Director and the CEO
“Option(s)”	option(s) to subscribe for or acquire Shares which is granted under the 2021 Share Option Scheme
“Proposed Connected Grant”	the proposed grant of 4,320,000 Award Shares to Mr. Liu and 137,000 Award Shares to Dr. Hu under the 2021 Share Award Scheme
“Remuneration Committee”	the remuneration committee of the Board
“R&D”	research and development
“Scheme Rules”	the rules of the 2021 Share Award Scheme as amended from time to time
“Selected Participant(s)”	any eligible person approved for participation in the 2021 Share Award Scheme and who has been granted any Award under the Grant of Awards, for the purpose of illustration in this announcement, excluding the Director(s)
“SFO”	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time

“Shareholder(s)”	the holder(s) of the Shares
“Share(s)”	ordinary share(s) in the capital of the Company with nominal value of US\$0.00001 each
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it by the Listing Rules
“Trustee”	Computershare Hong Kong Trustees Limited, the trustee that the Company engages for holding the Award Shares under the 2021 Share Award Scheme, which is independent of and not connected with the Company and its connected persons
“US\$”	United States dollars, the lawful currency of the United States of America
“%”	per cent

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, September 9, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.